Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

NAUT·NASDAQ

$2.58

-3.7%
HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

At a Glance

Live Snapshot
Market Cap$327.86M
EPS-0.4700
P/E Ratio-5.49
Earnings Date08/04/2026

naut

Long Term Debt

Last Annual Value

26.19M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

18%

Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Competitors Analysis of Long Term Debt

NAUT · NASDAQ
CompanyLong Term Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
26.19M
N/AN/AN/A 
7.81M
N/AN/AN/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
0.00
N/AN/AN/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
35.44M
-2.8%5.3%N/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
169.66M
136.9%67.6%2.7%
0.00
N/AN/AN/A
0.00
N/AN/AN/A
303.63K
-49.3%N/AN/A
Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Fair Value Envelope

NAUT · NASDAQ

Our analysis suggests that NAUT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.58, this represents a potential HIDDEN relative to our calculated worth for Nautilus Biotechnology, Inc..

Intrinsic Value
Current Price: $2.58